No Data
INNOVATIVE PHAR (00399.HK): Li Jiehong has been appointed as Executive Director.
Glory Financial on February 11 announced that INNOVATIVE PHAR (00399.HK) will implement the following changes from February 11, 2025: (i) Wu Yanmin has resigned as a non-executive Director; (ii) Xiao Yan has resigned as a non-executive Director; (iii) Li Jiehong has been appointed as an executive Director; (iv) Qi Shujuan has been appointed as an executive Director.
Express News | Innovative Pharmaceutical Biotech - Li Jiehong Has Been Appointed as an Executive Director
INNOVATIVE PHAR: Interim Report 2024-2025
INNOVATIVE PHAR plans to receive investment of 48 million HKD from new investors.
INNOVATIVE PHAR (00399) announced that on approximately December 10, 2024, the company will enter into a main agreement with investors...
Express News | Innovative Pharmaceutical Biotech - Investor Proposed to Acquire Certain Percentage of Shares of Co
innovative phar (00399.HK) mid-term attributable profit of approximately 0.102 billion Hong Kong dollars.
Grace 11th, innovative phar (00399.HK) announced that for the six months ended September 30, 2024, the group's revenue was approximately 3,000,000 Hong Kong dollars, a decrease of about 18.9% from the total revenue of approximately 3,700,000 Hong Kong dollars in the previous fiscal period. The decrease is mainly due to a decrease in business from the beauty equipment and product trading division during this fiscal period. During this fiscal period, the group recorded a profit attributable to owners of the company of approximately 101,700,000 Hong Kong dollars, compared to a profit of 193,700,000 Hong Kong dollars in the previous fiscal period. The profit for the two periods is attributed to the company.
Innovative Pharmaceutical Biotech (HKG:399) Is Posting Solid Earnings, But It Is Not All Good News
